Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.

Simonds NI, Khoury MJ, Schully SD, Armstrong K, Cohn WF, Fenstermacher DA, Ginsburg GS, Goddard KA, Knaus WA, Lyman GH, Ramsey SD, Xu J, Freedman AN.

J Natl Cancer Inst. 2013 Jul 3;105(13):929-36. doi: 10.1093/jnci/djt108. Epub 2013 May 9.

3.

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.

Goddard KA, Knaus WA, Whitlock E, Lyman GH, Feigelson HS, Schully SD, Ramsey S, Tunis S, Freedman AN, Khoury MJ, Veenstra DL.

Genet Med. 2012 Jul;14(7):633-42. Review.

4.

Lessons from comparative effectiveness research methods development projects funded under the Recovery Act.

Zurovac J, Esposito D.

J Comp Eff Res. 2014 Nov;3(6):601-7. doi: 10.2217/cer.14.64.

PMID:
25494566
5.

Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis.

Oderda GM, Balfe LM.

J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl B):S19-24.

6.

Multilevel research and the challenges of implementing genomic medicine.

Khoury MJ, Coates RJ, Fennell ML, Glasgow RE, Scheuner MT, Schully SD, Williams MS, Clauser SB.

J Natl Cancer Inst Monogr. 2012 May;2012(44):112-20. doi: 10.1093/jncimonographs/lgs003.

7.

Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute.

Hlatky MA, Douglas PS, Cook NL, Wells B, Benjamin EJ, Dickersin K, Goff DC, Hirsch AT, Hylek EM, Peterson ED, Roger VL, Selby JV, Udelson JE, Lauer MS.

J Am Coll Cardiol. 2012 Aug 14;60(7):569-80. doi: 10.1016/j.jacc.2011.12.057. Epub 2012 Jul 11.

8.

Comparative effectiveness research: a progress report.

Sox HC.

Ann Intern Med. 2010 Oct 5;153(7):469-72. doi: 10.7326/0003-4819-153-7-201010050-00269. Epub 2010 Aug 2.

PMID:
20679544
9.

Evaluating collaborations in comparative effectiveness research: opportunities and challenges for social network analysis.

Zickafoose JS, Kimmey LD, Tomas A, Esposito D, Rich E.

J Comp Eff Res. 2014 Nov;3(6):667-75. doi: 10.2217/cer.14.66.

PMID:
25494573
10.

Comparative effectiveness research in lung diseases and sleep disorders: recommendations from the National Heart, Lung, and Blood Institute workshop.

Lieu TA, Au D, Krishnan JA, Moss M, Selker H, Harabin A, Taggart V, Connors A; Comparative Effectiveness Research in Lung Diseases Workshop Panel.

Am J Respir Crit Care Med. 2011 Oct 1;184(7):848-56. doi: 10.1164/rccm.201104-0634WS.

11.

Can CER be an effective tool for change in the development and assessment of new drugs and technologies?

Brixner DI, Watkins JB.

J Manag Care Pharm. 2012 Jun;18(5 Supp A):S06-11.

PMID:
22663293
12.
14.

Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine.

Khoury MJ, Rich EC, Randhawa G, Teutsch SM, Niederhuber J.

Genet Med. 2009 Oct;11(10):707-11. doi: 10.1097/GIM.0b013e3181b99b90. Review.

PMID:
19752739
15.

American Society of Clinical Oncology Developing First Clinical Trial.

Brower V.

J Natl Cancer Inst. 2015 Nov 4;107(11):djv356. doi: 10.1093/jnci/djv356. Print 2015 Nov. No abstract available.

PMID:
26538625
16.

Developing a multidisciplinary model of comparative effectiveness research within a clinical and translational science award.

Marantz PR, Strelnick AH, Currie B, Bhalla R, Blank AE, Meissner P, Selwyn PA, Walker EA, Hsu DT, Shamoon H.

Acad Med. 2011 Jun;86(6):712-7. doi: 10.1097/ACM.0b013e318217ea82.

17.

The promise and future of comparative effectiveness research.

Clancy CM.

J Nurs Care Qual. 2010 Jan-Mar;25(1):1-4. doi: 10.1097/NCQ.0b013e3181c105b7. No abstract available.

PMID:
20010250
18.

Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations.

Manchikanti L, Falco FJ, Boswell MV, Hirsch JA.

Pain Physician. 2010 Jan-Feb;13(1):E23-54. Review.

19.

Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.

Bando H, Takebe N.

Jpn J Clin Oncol. 2015 Nov;45(11):1001-6. doi: 10.1093/jjco/hyv144. Epub 2015 Sep 29. Review.

20.

Personalized-medicine trials on the rise.

Benowitz S.

J Natl Cancer Inst. 2012 Oct 3;104(19):1425-6. doi: 10.1093/jnci/djs432. Epub 2012 Sep 24. No abstract available.

PMID:
23008496

Supplemental Content

Support Center